CLINICAL TRIALS PROFILE FOR PENICILLIN-VK

505(b)(2) Clinical Trials for Penicillin-vk

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Indication	NCT05069974 ↗	Alternative Antibiotics for Syphilis	Recruiting	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	Phase 3	2021-10-01	The Trep-AB clinical trial will test the efficacy of an investigational neuropenetrative drug, Linezolid (LZD), compared to standard treatment, Benzathine penicillin G (BPG), for early syphilis in humans. The overarching idea of the work proposed herein is to investigate the use of LZD to treat syphilis, conducting a randomized controlled clinical trial to evaluate this new indication of a known antibacterial agent. It is estimated to include 360 participants.

All Clinical Trials for Penicillin-vk

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000585 ↗	Penicillin Prophylaxis in Sickle Cell Disease (PROPS)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1983-08-01	To determine whether the regular daily administration of oral penicillin would reduce the incidence of documented infection due to Streptococcus pneumoniae in children with sickle cell anemia.
NCT00000648 ↗	A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals	Completed	Hoffmann-La Roche	N/A	1969-12-31	To provide information on the response of HIV infected, neurosyphilis patients to the currently recommended treatment for neurosyphilis; to determine whether possible co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to explore the usefulness of an alternative treatment which, if effective, would permit outpatient treatment for neurosyphilis that until now required prolonged hospitalization. Studies suggest that syphilis treatment failures may be more common in HIV infected patients than in patients without HIV infection and that treatment failures occur due to and/or are displayed as central nervous system (CNS) involvement. Very little is known about the best treatment course for neurosyphilis in patients who are also infected with HIV.
NCT00000648 ↗	A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To provide information on the response of HIV infected, neurosyphilis patients to the currently recommended treatment for neurosyphilis; to determine whether possible co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to explore the usefulness of an alternative treatment which, if effective, would permit outpatient treatment for neurosyphilis that until now required prolonged hospitalization. Studies suggest that syphilis treatment failures may be more common in HIV infected patients than in patients without HIV infection and that treatment failures occur due to and/or are displayed as central nervous system (CNS) involvement. Very little is known about the best treatment course for neurosyphilis in patients who are also infected with HIV.
NCT00001359 ↗	Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)	Completed	National Institute of Mental Health (NIMH)	Phase 2	1993-04-01	A subgroup of patients with childhood-onset obsessive-compulsive disorder (OCD) and/or tic disorders has been identified who share a common clinical course characterized by dramatic onset and symptom exacerbations following group A beta-hemolytic streptococcal (GABHS) infections. This subgroup is designated by the acronym PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections). There are five clinical characteristics that define the PANDAS subgroup: presence of OCD and/or tic disorder; prepubertal symptom onset; sudden onset or abrupt exacerbations (relapsing-remitting course); association with neurological abnormalities (presence of adventitious movements or motoric hyperactivity during exacerbations); and temporal association between symptom exacerbations and GABHS infections. In this subgroup, periodic exacerbations appear to be triggered by GABHS infections in a manner similar to that of Sydenham's chorea, the neurological variant of rheumatic fever. Rheumatic fever is a disorder with a presumed post-streptococcal autoimmune etiology. The streptococcal pathogenesis of rheumatic fever is supported by studies that have demonstrated the effectiveness of penicillin prophylaxis in preventing recurrences of this illness. A trial of penicillin prophylaxis in the PANDAS subgroup demonstrated that penicillin was not superior to placebo as prophylaxis against GABHS infections in these children, but this outcome was felt to be secondary to non-compliance with treatment, and there was no decrease in the number of neuropsychiatric symptom exacerbations in this group. In a study comparing azithromycin and penicillin, both drugs were completely effective in preventing streptococcal infections - there were no documented titer elevations during the year-long study period for children taking either penicillin or azithromycin. Comparable reductions in the severity of tics and obsessive-compulsive symptoms were also observed. Thus, penicillin was not performing as an "active placebo" as originally postulated, but rather provided effective prophylaxis against Group A beta-hemolytic streptococcal. Both azithromycin and penicillin appear to be effective in eliminating GABHS infections, and reducing neuropsychiatric symptom severity; thus, between-group differences are negligible. Since increasing the "n" to demonstrate superiority of one prophylactic agent over another would be impractical, we have amended the study design to address two issues: 1. To determine if antibiotics prophylaxis against GABHS infections is superior to placebo in prolonging periods of remission among children in the PANDAS subgroup. 2. To determine if antibiotics prophylaxis against GABHS infections is superior to placebo in improving overall symptom severity for obsessive-compulsive symptoms and tics among children in the PANDAS subgroup. Because penicillin has a narrower therapeutic index and is less expensive than azithromycin, it is the preferable prophylactic agent. Further, penicillin (250 mg orally twice a day) has a long history of providing safe and effective prophylaxis for rheumatic fever and is the first line oral therapy recommended by the American Heart Association. Thus, penicillin has been chosen as the prophylactic antibiotic in the present study. Blister packs are used to increase compliance and to allow for easier documentation of missed doses.
NCT00002682 ↗	Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach	Completed	National Cancer Institute (NCI)	Phase 2	1995-08-10	RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.
NCT00002682 ↗	Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach	Completed	M.D. Anderson Cancer Center	Phase 2	1995-08-10	RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.

Clinical Trial Conditions for Penicillin-vk

Condition Name

Condition Name for Penicillin-vk
Intervention	Trials
Syphilis	12
Penicillin Allergy	11
Helicobacter Pylori Infection	10
Pneumonia	7

Condition MeSH

Condition MeSH for Penicillin-vk
Intervention	Trials
Infections	33
Infection	25
Communicable Diseases	24
Syphilis	17

Clinical Trial Locations for Penicillin-vk

Trials by Country

Trials by Country for Penicillin-vk
Location	Trials
United States	206
China	25
Canada	21
Australia	18
Israel	11

Trials by US State

Trials by US State for Penicillin-vk
Location	Trials
California	15
Ohio	12
New York	12
Texas	11
North Carolina	9

Clinical Trial Progress for Penicillin-vk

Clinical Trial Phase

Clinical Trial Phase for Penicillin-vk
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	6
PHASE2	5

Clinical Trial Status

Clinical Trial Status for Penicillin-vk
Clinical Trial Phase	Trials
Completed	89
RECRUITING	37
Not yet recruiting	27

Clinical Trial Sponsors for Penicillin-vk

Sponsor Name

Sponsor Name for Penicillin-vk
Sponsor	Trials
World Health Organization	7
National Institute of Allergy and Infectious Diseases (NIAID)	6
University of Oxford	5

Sponsor Type

Sponsor Type for Penicillin-vk
Sponsor	Trials
Other	379
Industry	26
NIH	11

Penicillin-vk Market Analysis and Financial Projection

Last updated: April 28, 2026

Penicillin-VK Clinical Trials Update and Market Analysis

Penicillin-VK (phenoxymethylpenicillin; oral phenoxymethylpenicillin potassium) is an established, off-patent oral beta-lactam antibiotic used for infections where penicillin activity is appropriate. Current R&D signals and trial activity are limited and largely do not support a near-term, drug-specific “pipeline” expansion narrative. The market is sustained by generic penetration, broad clinician familiarity, and narrow-indication use patterns shaped by antimicrobial stewardship and resistance trends rather than by new clinical differentiation.

---

What does the clinical-trials landscape look like for Penicillin-VK?

Penicillin-VK’s clinical development footprint is dominated by: (1) legacy trials and post-marketing safety use rather than active efficacy programs, and (2) formulation or comparator studies carried out at pharmacy/generic-manufacturing scale rather than by new-chemical-entity sponsors. As a result, trial “updates” are often not meaningful for investors seeking a discrete, sponsor-led late-stage catalyst.

Trial activity: what is typical for Penicillin-VK

Common study types reported for older, generic antibiotics include:

• Microbiological and susceptibility surveillance publications (organism coverage rather than randomized efficacy endpoints).
• Small comparator studies tied to guideline-concordant regimens, often without clear differentiation versus amoxicillin or broader-spectrum alternatives.
• Bioequivalence and formulation equivalence studies (where applicable), which do not create an efficacy re-positioning claim.

Clinical relevance drivers

Penicillin-VK’s practical clinical demand is shaped by:

• Continued guideline positioning for susceptible streptococcal syndromes and selected dental/ENT infections, where penicillin remains preferred if susceptibility is confirmed.
• Stewardship pressures that push prescribers toward narrowest effective therapy when data support it.
• Ongoing shifts in local resistance patterns that can reduce empiric use and increase reliance on susceptibility testing.

---

What markets matter most for Penicillin-VK and why?

Penicillin-VK’s demand is structural, not aspirational. Sales track infection incidence in primary care and dentistry, guideline preference for narrow-spectrum beta-lactams, and local payer formularies. The drug’s market profile is therefore dominated by generic availability and supply chain stability.

Demand centers

The largest commercial pull historically comes from:

• High outpatient volumes with routine treatment for susceptible infections.
• Dental and ENT care pathways where penicillin-class drugs are used for specific etiologies.
• Institutional healthcare systems that stock older oral antibiotics for standard indications.

Pricing and competitive structure

Penicillin-VK is typically sold as generics, so commercial performance is driven by:

• Wholesale acquisition cost compression and payer formularies.
• Batch manufacturing efficiency and compliance reliability.
• Interchangeability between oral beta-lactams (penicillin VK vs amoxicillin vs narrow penicillin alternatives), depending on local labeling and coverage.

Substitution pressures

In many regions, substitution risk increases because:

• Amoxicillin is often the default narrow beta-lactam for common outpatient infections due to broader dosing convenience and clinician familiarity.
• Broader-spectrum agents gain share when culture data are delayed or when empiric coverage needs expand.
• Resistance and treatment failures push clinicians toward alternatives in practice, even when susceptibility testing is not always performed.

---

How should you project the Penicillin-VK market?

Projection for penicillin-VK should be built around three levers: (1) persistent baseline use in susceptible indications, (2) antimicrobial stewardship and resistance-driven dampening of empiric use, and (3) generic pricing and volume dynamics.

Projection framework (directional, decision-grade)

Base-case mechanics

• Volume: steady-to-slightly down over time in mature markets due to stewardship and regimen substitution toward amoxicillin and other narrow agents in comparable settings.
• Price: generally flat-to-down given generic competition, with intermittent volatility from supply constraints.
• Value: grows slowly or remains flat depending on mix and regional reimbursement.

Bull-case mechanics

• Volume: stabilized by stable guidance adherence and persistent penicillin VK preference in select indications.
• Price: supported by supply tightness or constrained manufacturing capacity.
• Mix: shift toward higher-need outpatient segments (dental/ENT) where oral penicillin remains in use.

Bear-case mechanics

• Volume: declines as local resistance trends reduce empiric appropriateness and increase switch to other agents.
• Price: pressured by margin competition and expanded generic entries.
• Policy: stricter stewardship further reduces narrow beta-lactam selection when testing is not performed.

Practical ranges to guide underwriting

Because Penicillin-VK is off-patent with multiple generic players, underwriting should emphasize supply and formulary retention more than “innovation-led” growth. A reasonable projection stance for mature markets is:

• Value: low single-digit CAGR or flat over a typical investment horizon.
• Volume: flat to modest decline, with step-changes possible only from reimbursement/formulary shifts or supply disruptions.

---

What commercial risks and upside signals should be monitored?

Key downside risks

• Guideline substitution: steady movement toward other narrow beta-lactams if prescribers optimize for dosing schedules or perceived spectrum.
• Resistance ecology: local resistance trends that reduce presumptive use.
• Supply disruptions: generic antibiotic markets are sensitive to plant downtime and raw material constraints.
• Pricing compression: increased competition can rapidly erode value even if volume holds.

Key upside signals

• Formulary wins: durable inclusion in payer outpatient lists for relevant indications.
• Stewardship alignment: penicillin VK used as narrowest effective option in protocols that emphasize culture when feasible.
• Stable manufacturing capacity: reliable supply can protect share when competitors face shortages.

---

What does this mean for R&D strategy (if a sponsor is involved)?

Penicillin-VK’s R&D value creation is mostly limited to:

• Formulation or regulatory lifecycle work (bioequivalence, stability, line extensions where legally relevant).
• Label-expansion through new clinical evidence is rare for an established antibiotic class unless a specific unmet niche is targeted by a sponsor.

If a sponsor targets differentiation, the credible paths are:

• Resistance-informed stewardship labeling that aligns with susceptibility confirmation practices.
• Pharmacokinetic/pharmacodynamic (PK/PD) substantiation for specific dosing regimens in targeted populations.

In practice, investor-grade catalysts usually come from adjacent assets or from antibiotic class strategies rather than from new penicillin VK efficacy claims.

---

Key Takeaways

• Penicillin-VK is an established, off-patent antibiotic; trial updates are typically limited to post-marketing use, surveillance, and formulation/BI-equivalence studies rather than new late-stage efficacy programs.
• Market dynamics are dominated by generic pricing, payer/formulary retention, and guideline-driven prescribing patterns under antimicrobial stewardship.
• Near-term growth is likely low single-digit or flat in mature markets, with sensitivity to local resistance trends and supply stability.
• The most material monitors are formulary placement durability, local susceptibility ecology, and manufacturing/supply continuity rather than a new-chemical-entity pipeline build.

---

FAQs

1) Is Penicillin-VK still used clinically?
Yes. It remains used for susceptible infections aligned with penicillin-class activity in outpatient pathways, including selected ENT and dental indications.

2) What type of clinical trials dominate for Penicillin-VK?
The footprint is generally tied to legacy evidence, post-marketing safety experience, susceptibility context, and where applicable, bioequivalence or formulation equivalence work.

3) What drives demand more: resistance or stewardship?
Both. Resistance reduces empiric appropriateness; stewardship reduces unnecessary broad use and pushes selection toward narrow agents only when clinically justified.

4) How competitive is the Penicillin-VK market?
Highly. Generic penetration compresses pricing and shifts competition toward formulary access and supply reliability.

5) Where are the biggest commercial risks?
Formulary substitution to other narrow beta-lactams, resistance-driven prescribing changes, and manufacturing or supply-chain disruptions that affect availability.

---

References

[1] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Penicillin V potassium / phenoxymethylpenicillin potassium).
[2] EMA. Public assessment reports and EPAR-related documentation where applicable for phenoxymethylpenicillin products.
[3] WHO. Antimicrobial resistance surveillance and antibiotic stewardship guidance (relevant principles for outpatient beta-lactam use).